Krystal J et al., 2024-01-17: Phase 1 trial of mebendazole with bevacizumab and irinotecan in 10 children and young adults with high-grade glioma. It reports no dose-limiting toxicity up to 200 mg/kg/day and a 33% overall response rate.
The overall response rate was 33%, with two subjects achieving a partial response and one subject achieving a complete response sustained for 10 months.
n/a
Krystal J et al., 2024-01-17: Phase 1 trial of mebendazole with bevacizumab and irinotecan in 10 children and young adults with high-grade glioma. It reports no dose-limiting toxicity up to 200 mg/kg/day and a 33% overall response rate. Study type: phase 1, 3+3 dose escalation, single arm. N=10 (7 diffuse midline glioma, 1 anaplastic astrocytoma, 1 spinal high-grade glioma). Country: United States (Cohen Children's Medical Center, New York). Dose: mebendazole 50, 100 or 200 mg/kg/day orally twice daily continuously with bevacizumab 10 mg/kg/dose and irinotecan 150 mg/m2/dose on days 1 and 15 of 28-day cycles. Funder: not stated in the PubMed record. Conflicts: not stated in the PubMed record; full text not open. Maker: not stated. Comparator: none. Mean PFS 4.7 months and OS 11.4 months from start of study treatment. Also filed as MBD-13 (claims C2, C3).
